Kodiak Sciences Inc. (K27)
FSX
Closed
Oct 9, 2026
Day's Range
83.6052 wk Range
9.72Overview - K27 - Kodiak Sciences Inc.
Key Statistics
Valuation
Enterprise Value
4.61B
P/E (Trailing)
‪-19.05‬
P/E (Forward)
‪-13.80‬
PEG Ratio
‪-9.81‬
Price / Book
‪95.88‬
EV / EBITDA
‪-22.49‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-60.44%‬
Return on Equity
‪-368.37%‬
Ownership
Shares Outstanding
62.83M
Float
36.86M
Held by Insiders
‪5.16%‬
Held by Institutions
‪105.56%‬
Price stats
Beta
‪2.03‬
50-Day Avg
‪37.36‬
200-Day Avg
‪30.53‬
Market Cap - K27 - Kodiak Sciences Inc.
Peers - K27 - Kodiak Sciences Inc.
Peer Comparison
Compared with companies in Biotechnology listed on FSX.
- K27FSXKodiak Sciences Inc.5.17BMarket Cap+85.25%52-week change-19.05P/E (Trailing)‪0.00%‬Profit Margin
- ANLFSXAnalog Devices Inc.179.11BMarket Cap+43.92%52-week change47.10P/E (Trailing)‪29.78%‬Profit Margin
- 0QFFSXModerna Inc.69.12BMarket Cap+87.76%52-week change25.27P/E (Trailing)‪-141.42%‬Profit Margin
- 64BFSXAstera Labs, Inc.53.43BMarket Cap+42.53%52-week change179.66P/E (Trailing)‪30.74%‬Profit Margin
- 1AEFSXargenx SE52.63BMarket Cap+28.29%52-week change36.62P/E (Trailing)‪32.26%‬Profit Margin
- 1AEAFSXargenx SE American Depositary Receipt50.36BMarket Cap+25.47%52-week change34.88P/E (Trailing)‪32.26%‬Profit Margin
- 42ZFSXRevolution Medicines, Inc.37.58BMarket Cap+78.78%52-week change-29.47P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - K27 - Kodiak Sciences Inc.
About
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases. The company works on treatments for conditions that affect the retina and can lead to vision loss, with a portfolio centered on ophthalmology and retinal vascular disorders. Its current programs…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
